Fox Business - The Power to Prosper
Search Site

Ranbaxy Laboratories

Related Topics

  1. Abbott Laboratories
  2. Fukushima Nuclear Power Plant
  3. Pfizer
  4. IMS Health
  5. Watson Pharmaceuticals
  6. Pharmaceuticals
Get updates on Ranbaxy Laboratories
Ranbaxy to Pay $500 Million in Adulterated Drugs Case

Indian generic pharmaceutical maker Ranbaxy Laboratories Ltd.'s (500359.BY) U.S. subsidiary has pled guilty to felony charges relating to adulterated drugs made at two of Ranbaxy's manufacturing facilities in India, according to the Department of Justice.Ranbaxy agreed to pay a criminal fine and forfeiture totaling $150 million and to settle civil claims for $350 million in the largest drug-safety settlement to date with a generic drug manufacturer.Ranbaxy USA pleaded guilty to three felony counts under the Food, Drug and Cosmetic Act--which prohibits adulterated drugs--and four felony counts of knowingly making material false statements to the U.S. Food and Drug Administration.The generic drugs at issue were manufactured at Ranbaxy's facilities in Paonta Sahib and Dewas, India. They include acne drug Sotret, epilepsy and nerve pain drug gabapentin, and antibiotic ciprofloxacin."When companies sell adulterated drugs, they undermine the integrity of the FDA's approval process and may ca...

Read More ›

  1. Pfizer Sued for Conspiring to Delay Generic Lipitor

    Pfizer (NYSE:PFE) has been sued by five big retailers for allegedly conspiring to delay sales of generic versions of blockbuster drug Lipitor.The drug maker lost pat...

  2. Dr Reddy's Jan-March Net Grows 2.7%; Misses View On One-Time Charge

    Dr. Reddy's Laboratories Ltd. (500124.BY) Friday disappointed investors with a slim 2.7% rise in its fourth-quarter net profit, but this was due mainly to a one-time...

  3. Teva 1Q Profit Up 13% On Branded, Generic Drug Sales

    Teva Pharmaceutical Industries Ltd. (TEVA) said Wednesday its first-quarter profit rose 13%, as sales growth for branded and generic drugs in the U.S. and emerging m...

  4. Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales

    Pfizer Inc.'s (PFE) first-quarter profit declined 19% as sales of its top product, the cholesterol-lowering drug Lipitor, tumbled 71% in the U.S. due to competition ...

  5. UPDATE: Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales

    ("UPDATE: Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales," published at 9:01 a.m. EDT, incorrectly stated sales for Prevnar 13 in the eleventh paragraph. A c...

  6. Ranbaxy Starts Selling Generic Atorvastatin In Australia

    India's Ranbaxy Laboratories Ltd. (500359.BY) Tuesday said it has become the first generic drug maker to started selling generic cholesterol drug atorvastatin in Aus...

  7. Watson Pharma 4Q Profit Surges On Generic Lipitor, Concerta

    Watson Pharmaceuticals Inc.'s (WPI) fourth-quarter profit surged as the introduction of a generic version of Pfizer Inc.'s (PFE) cholesterol drug Lipitor and other p...

  8. Japan Stocks Open Lower, With Earnings Dragging

    Japanese stocks moved lower in early Wednesday trading, with a weak finish on Wall Street and disappointing earnings at home weighing on the market. The Nikkei Stock...

  9. Patent Losses Hit Pfizer, Lilly As Both Await Alzheimer's Drug Data

    Drug makers Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) fell off the so-called "patent cliff," each reporting declines in fourth-quarter profits due to new generic c...

  10. Pfizer 4Q Profit Slumps 50% As Lipitor Sales Decline

    Pfizer Inc.'s (PFE) fourth-quarter profit declined 50% as sales of its widely used cholesterol drug Lipitor tumbled due to new generic competition.The New York drug ...

  11. Benefit Manager's Lipitor Move Highlights Pressure On Pfizer

    Pharmacy-benefit manager Express Scripts Inc. (ESRX) will soon make an adjustment that raises out-of-pocket costs for some customers filling prescriptions of Pfizer ...

  12. Generic Lipitor About to Hit the Market

    Pfizer just lost exclusive marketing rights for one of the top-selling drugs in the country, Lipitor.  The world’s largest drug company’s rights to the cholesterol-l...

  1. Ranbaxy to Pay $500 Million in Adulterated Drugs Case; Largest Such Settlement Ever

    Indian generic pharmaceutical maker Ranbaxy Laboratories Ltd.'s (500359.BY) U.S. subsidiary has pled guilty to felony charges relating to adulterated drugs made at t...

  2. Astellas, Daiichi Sankyo See New Drugs Propelling Growth

    Japan's second and third largest drug makers on Monday predicted growth in the current fiscal year as they battle to offset large-scale revenue fallout from patent e...

  3. Novartis Boosted by Drug Launches

    Swiss drug maker Novartis AG (NOVN.VX) Wednesday posted a rise in first-quarter net profit, as new product launches and strength in emerging markets helped offset de...

  4. Ranbaxy Resumes Generic Lipitor Production for U.S.

    Ranbaxy Laboratories Ltd. (500359.BY) said Friday it has resumed manufacturing generic copies of the cholesterol-lowering drug Lipitor for the U.S. market, following...

  5. Ranbaxy Had Smaller Recall of Generic Lipitor in August Over Pill Mix-up

    Ranbaxy Laboratories Ltd. (500359.BY) recalled more than 32,000 bottles of its generic version of cholesterol-lowering drug Lipitor over a potential pill mix-up in A...

  6. Malaysia Unveils MYR5.61 Billion of Investments Via 7 New Projects

    Malaysia Thursday announced seven new projects worth a total of 5.61 billion ringgit ($1.82 billion) ranging from a liquefied natural gas terminal to a drug manufact...

  7. Malaysia PM: Attracted 7 New Projects Worth MYR5.61 Billion

    Malaysia announced Thursday a slew of new projects worth a total of 5.61 billion Malaysian ringgit ($1.82 billion) in investments, as part of its broader ambition to...

‹ Prev12Next ›
Freebase CC-BY
Source: Ranbaxy Laboratories on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL